Special Issue

Research Therapeutic Strategies for Alzheimer's Disease Treatments

Message from the Guest Editor

Alzheimer's disease is the most common form of dementia. AD is associated with the formation of \(\mathbb{L}-\) amyloid plagues and neurofibrillary tangles in the brain. However, findings have shown that the accumulation of All plaques is not sufficient to cause the disease. The acute inflammation may play a pivotal role in brain function, promoted by astrocytes activation and the production of proinflammatory markers. There is no effective therapeutic strategy that is capable of stopping or reverting the disease's progress because of the low drug solubility, rapid metabolism, or inability to cross the blood-brain barrier to reach brain parenchyma. Therefore, finding new therapies for treating Alzheimer's disease and other dementias remains a challenge. Nanoparticles have displayed potential for encapsulating small molecule drugs, cross the bloodbrain barrier, making nanomaterials a possibility for the treatment of Alzheimer's disease. This Special Issue of the journal *Pharmaceutics* aims to improve our understanding of the therapeutic strategies of nanomaterials in the field of Alzheimer's disease and other dementias.

Guest Editor

Dr. Santiago Grijalvo

- 1. Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain
- 2. Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Jordi Girona 18-26, E-08034 Barcelona, Spain

Deadline for manuscript submissions

closed (30 June 2021)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/70033

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

